Metastatic Colorectal Cancer Market is segmented By Therapy (Immunotherapy, Chemotherapy, Targeted Therapy, Others), By End-use (Hospitals and Clinics....
Market Size in USD
CAGR8.1%
Study Period | 2024 - 2031 |
Base Year of Estimation | 2023 |
CAGR | 8.1% |
Market Concentration | High |
Major Players | Amgen, Pfizer, Nurix Therapeutics Inc., Sumitomo Dainippon Pharma Oncology, Merck |
The Global Metastatic Colorectal Cancer Market is estimated to be valued at USD 10.11 billion in 2024 and is expected to reach USD 27.32 billion by 2031, growing at a compound annual growth rate (CAGR) of 8.1% from 2024 to 2031. Advances in targeted therapies and immunotherapy has led to improved clinical outcomes for metastatic colorectal cancer patients.
The market is set to witness significant growth owing to rising incidence of colorectal cancer worldwide and launch of novel targeted therapies and immunotherapies in the forecast period. Increased research and development activities for drug development by key players will also drive the market. However, complexity of cancer treatment and high cost of therapies will challenge market growth to some extent in the coming years.